Interestingly, the hybrid CB1 and iNOS antagonist MRI-1867 helped reverse obesity-induced CKD by improving the metabolic profile, kidney morphology and function, inflammation and fibrosis [63]. The gene discussed is CNR1; the disease is obesity due to melanocortin 4 receptor deficiency.